TNYA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tenaya Therapeutics Inc (TNYA) is not a good buy for a beginner investor with a long-term focus at this time. The stock demonstrates weak financial performance, bearish technical indicators, insider selling, and lacks positive catalysts or strong signals from proprietary trading tools. Additionally, the analyst's price target reduction and lack of recent news further diminish its attractiveness.
The technical indicators for TNYA are bearish. The MACD is negatively expanding (-0.0141), RSI is neutral at 25.742, and moving averages indicate a downtrend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels (Pivot: 0.793, current price: 0.7009), with support at 0.705 and resistance at 0.88.
NULL identified. No recent news or significant positive developments.
Insider selling has increased significantly (55373.56% in the last month).
Analysts have lowered the price target from $5 to $2, reflecting diminished confidence.
Weak financial performance with declining net income (-15.36% YoY) and EPS (-57.14% YoY).
No recent congress trading data or influential figure activity.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$20.175M (-15.36% YoY), and a significant EPS decline (-57.14% YoY). Gross margin remains at 0%. The financials indicate poor growth trends and a lack of profitability.
Morgan Stanley has reduced the price target from $5 to $2 while maintaining an Overweight rating. The analyst notes challenges for small-to-mid cap biotech companies, despite potential long-term industry tailwinds.
